Temporal trends in the progression of human immunodeficiency virus disease in a cohort of drug users

Epidemiology

Volumn 9, Issue 6, 1998, Pages 613-617

  Webber, Mayris P ^a,b   Schoenbaum, Ellie E ^a   Gourevitch, Marc N ^a   Buono, Donna ^a   Chang, Chee Jen ^a   Klein, Robert S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Injection drug users; Methadone maintenance; Primary care; Progression to AIDS

Indexed keywords

AMPHETAMINE; COCAINE; DIAMORPHINE; METHADONE; OPIATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPPORTUNISTIC INFECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0031697945     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199811000-00008     Document Type: Article

References (34)

1. Rosenberg P, Gail M, Schrager L, Vermund SH, Creagh-Kirk T, Andrews EB, Winklestein W, Marmor M, DesJarlais DC, Biggar RJ, Goedert JJ. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic transmission groups. J Acquit Immune Defic Syndr 1991;4:392-401.
2. Schwartzlander B, Horsburgh CR, Hamouda O, Skarabis H, Koch MA. Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. AIDS 1992;6:413-420.
3. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, Kaslow R, Multicenter AIDS Cohort Study. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993;329:1922-1926.
4. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, AIDS Clinical Trials Group. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112:727-737.
5. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-949.
6. Graham NMH, Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR, Phair JP, Multicenter AIDS Cohort Study. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-269.
7. Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J, Stevens JW, Fiddian AP, European-Australian Collaborative Group. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993;329:297-303.
8. Vella S, Giuliano M, Dally LG, Grazia Agresti M, Tomino C, Floridia M, Chiesi A, Fragola V, Moroni M, Piazza M, Scalise G, Ortona L, Aiuti F, Lazzarin A, Piero Carosi G, Bassetti D, Guzzanti E, Dianzani F, Italian Zidovudine Evaluation Group. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. J Acquir Immune Defic Syndr 1994;7:31-38.
9. Moore RD, Stanton DL, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-768.
10. Bozek PS, Weidle PJ, Perdue BE, Everson RE. The use of antiretroviral therapy in association with evolving standards of practice (Abstract). Fourth Conference on Retroviruses and Opportunistic Infections, Washington DC, January 1997.
11. Schoenbaum EE, Hartel DM, Selwyn PA, Klein RS, Davenny K, Rogers M, Feiner C, Friedland G. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 1989;321:874-879.
12. Selwyn PA, Alcabes PA, Hartel DM, Buono D, Schoenbaum EE, Klein RS. Clinical manifestations and predictors of disease progression in injecting drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-1703.
13. Selwyn PA, Feingold AR, Iezza A, Satyadeo M, Colley J, Torres R, Shaw JFM. Primary care for patients with human immunodeficiency virus infection in a methadone maintenance treatment program. Ann Intern Med 1989;111:761-763.
14. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
15. Alcabes P, Selwyn PA, Davenny K, Hartel D, Buono D, Schoenbaum EE, Klein RS, Friedland GH. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994;8:107-115.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall, 1984.
18. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989;38:1-9.
19. Munoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R, Saah AJ, Kingsley LA, Seminara D, Phair JP. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993;137:423-438.
20. Demas P, Schoenbaum EE, Hirky AE, Wills TA, Doll LS, Hartel DM, Klein RS. The relationship of HIV treatment acceptance and adherence to psychosocial factors among injecting drug users. AIDS Behav (in press).
21. Sackett DL, Snow JC. In: Haynes R, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: Johns Hopkins Universiry Press, 1979; 11-22.
22. Des Jarlais D, Friedman S, Novick D, Sotheran JL, Thomas P, Yancovitz SR, Mildvan D, Weber J, Kreek MJ, Maslansky R, Bartelme S, Spira T, Marmor M. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 1989;261:1008-1012.
23. Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of AIDS in injecting drug users. Ann Epidemiol 1994;4:17-26.
24. Sinicco A, Fora R, Raiteri R, Sciandra M, Calvo P, Gioannini P. Is the clinical course of HIV-1 changing? Cohort study. BMJ 1997;314:1232-1237.
25. Carer N, Prins M, Meyer L, Brettle RP, Robertson JR, McArdle H, Goldberg DJ, Zangerle R, Coutinho RA, van den Hoek A. Has the rate of progression to AIDS changed in recent years? AIDS 1997;11:1611-1618.
26. Glesby M, Hoover D. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996;124:999-1005.
27. Lepri AC, Sabin CA, Phillips AN. Investigating temporal changes in the rate of HIV progression: challenges and limitations. AIDS 1997;11:1647-1649.
28. Phillips A, Sabin C, Elford J, Bofill M, Janossy G, Lee CA. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts. Am J Epidemiol 1993;138:870-878.
29. Phillips AN, Pezzotti P, Lepri AC, Rezza G, Italian Seroconversion Study. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994;8:1299-1305.
30. Shi M, Taylor JMG, Currier RJ, Tang H, Hoover DR, Chmiel JS, Bryant JL, Multicenter AIDS Cohort Study. Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. J Acquir Immune Defic Syndr 1996;12:309-316.
31. Yong FHL, Taylor JMG, Bryant JL, Chmiel JS, Gange SJ, Hoover D. Dependence of the hazard of AIDS on markers. AIDS 1997;11:217-228.
32. Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, Muñoz A. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996;275:1329-1334.
33. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994;271:1083-1087.
34. Chiasson MA, Berenson L, LI W, Schwartz S, Mojica B, Hamburg M. Declining AIDS mortality in New York City (NYC) (Abstract). Fourth Conference on Retroviruses and Opportunistic Infections, Washington DC, January 1997.